📄 What This Document Is 📰

This document is an 8-K, or a Current Report, which means Amneal is filing an urgent update with the SEC to inform the public about a major, material event that happened on or around April 22, 2026. Since the filing centers entirely on a large deal, it provides the detailed legal contract (the Purchase Agreement) governing the acquisition. 👉 Expect to read about the specific terms of the deal, including how much Amneal is paying, what conditions must be met for future payments, and how the deal's financials will be managed post-closing.

🏢 What Amneal Does 💊

Amneal Pharmaceuticals is a major pharmaceutical company that focuses on the development, manufacturing, and commercialization of drugs. It operates within the complex world of biosimilars and biological products, which are highly complex medicines designed to mimic existing, patented drugs. 👉 Simply put, Amneal is buying a specialized asset (Kashiv BioSciences) to grow its pipeline of drugs that help patients.

🤝 The Acquisition of Kashiv BioSciences 🌟

Amneal has announced a massive deal to acquire 100% of the membership interests of Kashiv BioSciences, LLC. This acquisition is intended to significantly strengthen Amneal's product portfolio and market presence in the pharmaceutical space. The deal was formalized by signing the Membership Interest Purchase Agreement on April 21, 2026, with Kashiv and its sellers.

👉 The primary goal is for Amneal to gain immediate access to Kashiv's drug candidates, bolstering Amneal's competitive edge in the biosimilar market.

💰 Initial Payment & Consideration 💵

The immediate payment and financial structure of this acquisition are complex, involving a combination of cash, stock, and future contingent payments. This structure is designed to distribute risk and reward both the sellers and the buyers.

• Initial Cash Payment: Amneal agreed to pay an initial cash amount of $375,000,000 to the sellers.
  • Why it matters: This upfront payment provides immediate liquidity and signals Amneal's commitment to the deal.
• Equity Consideration: In addition to cash, Amneal will issue 28,942,108 shares of Amneal Class A common stock.
  • Why it matters: Stock consideration means the sellers are partially paid with ownership in Amneal, making them vested partners in the company's future success.
• Transaction Adjustments: The initial cash payment is subject to several adjustments, including for working capital fluctuations, funding of operations, and transaction expenses.
  • Why it matters: These clauses protect Amneal by ensuring the true financial health of the acquired company (Kashiv) is accounted for before the final payout.

🏆 Contingent Milestone Payments 🏅

A large portion of the potential deal value is tied to milestones—meaning the sellers will receive payments only if certain drugs successfully pass regulatory hurdles. These payments are structured into "First Tranche" and "Second Tranche" groups.

👉 The maximum potential for Milestone Payments is highly significant, up to $400,000,000 ($250M + $100M), showing that future FDA approvals are critical to the deal’s total value.

First Tranche Milestones (Major Regulatory Approvals)

These payments are tied to products achieving key regulatory milestones before their set deadlines:

• Abatacept Product (bOrencia): The first $50,000,000 payment is due if it achieves regulatory approval for multiple delivery types by 9/30/2028, or if it is the first or second biosimilar to meet that condition by the "Fifth Anniversary."
• Certolizumab pegol Product (bCimzia): This is worth up to $50,000,000 if it achieves approval by 12/31/2028 or meets the "first or second" condition by the Fifth Anniversary.
• Dulaglutide Product (bTrulicity): Worth up to $25,000,000 upon approval by 12/31/2028, or meeting the "first or second" condition by the Fifth Anniversary.
• Omalizumab Product (bXolair): Up to $50,000,000 if it achieves approval by 9/30/2027, or meets the "first or second" condition by the Fifth Anniversary.
• Pancrelipase Product (bCreon): Worth up to $50,000,000 if it achieves approval by 12/31/2028, or meets the "first or second" condition by the Fifth Anniversary.
• Romiplostim Product (bNplate): Up to $25,000,000 if it achieves approval by 9/30/2028, or meets the "first or second" condition by the Fifth Anniversary.

Second Tranche Milestone (Pancrelipase)

The Pancrelipase product has a second milestone worth $100,000,000. This is a highly specific, conjunctive trigger (meaning both conditions must be met) that requires the product to:

1. Commercially launch in the U.S. by the Pancrelipase Trigger Date.
2. AND have no more than one other biosimilar to launch in the U.S. within the subsequent twelve months.

💸 Long-Term Royalty Payments 👑

Beyond the big milestones, the agreement includes royalties, which provide a continuous revenue stream for the sellers over the long haul. Amneal will pay a royalty based on the gross profits generated by certain products.

• Payment Terms: Amneal must pay 25% of the amount by which the annual aggregate gross profits exceed a specified "Excluded Profit" hurdle.
• Payment Duration: This royalty stream runs for a twelve (12)-year period starting after the Closing Date.
• Annual Schedule: The payments are structured annually, with increasing "Excluded Profit" thresholds set out through 2039. For example, the Excluded Profit for the 2028 Royalty Period is set at $221,475,000.
  • Why it matters: This structure ensures that as the drugs mature and become more profitable, the royalties paid to the sellers also increase, protecting the sellers' investment decades into the future.

⚙️ Post-Closing Financial Adjustments 📉

The Purchase Agreement details meticulous mechanics for how the final dollar amount is calculated after the deal closes. These adjustments ensure that the transaction accounts for the true financial state of the companies.

• Working Capital: This adjusts the payment based on the difference between the actual and expected operating capital of the acquired company.
• Closing Indebtedness & Transaction Expenses: The payment is adjusted by any remaining debt or transaction expenses (like legal fees) that need to be paid off after the closing date.
• Escrow Accounts: Amneal and the sellers must fund two escrow accounts: one for the Adjustment Escrow Funds and one for the Retention Bonus Escrow Funds. These funds act as a financial guarantee to cover potential shortfalls in final payments.

📜 Ancillary Agreements and Governance 🛡️

The purchase of the company assets is wrapped in several supporting agreements that protect Amneal's interests and define the relationship between the parties.

• Restrictive Covenants: Amneal entered into Restrictive Covenants Agreements with Chirag Patel and Chintu Patel. These agreements prohibit them from competing with Kashiv or soliciting employees for five years after the closing.
• Stockholders Agreement: The Company also agreed to a First Amendment to the Third Amended and Restated Stockholders Agreement with Vikram Patel, aiming to amend the definition of "Amneal Group."
  • Why it matters: These covenants are vital for Amneal; they protect its intellectual property and market exclusivity by restraining key individuals from competing immediately after the deal closes.

📣 Operational & Financial Updates 📊

In addition to the major acquisition, Amneal also issued a preliminary financial report covering the first quarter of 2026 (for the quarter ended March 31, 2026). This shows the market that Amneal is actively reporting on its current financial performance while managing the massive acquisition.

• Note: The full details of the preliminary Q1 2026 results are provided in an attached press release (Exhibit 99.1).

📅 Future Communications and Key Dates 📞

Amneal has announced how investors can learn more about the deal and the Q1 results. These details are crucial for understanding the timeline and getting timely information.

• Conference Call: Amneal will host a conference call and live webcast on April 22, 2026, at 8:30 am Eastern Time.
• Purpose: The call will discuss the announced Acquisition and the preliminary first quarter 2026 results.
• Access: The call will be accessible through the Investor Relations section of the company's website.

📍 Investor Relations and Contacts 📧

For detailed follow-up questions about the deal or the company's finances, Amneal has provided specific contact information for investors.

• Address: Investor Relations, 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807
• Phone: (908) 947-3120
• Email: [email protected]

🧠 The Analogy 💡

Think of Amneal purchasing Kashiv as buying a highly specialized, sophisticated Swiss watch workshop. Instead of simply buying the existing clocks, Amneal is paying a massive deposit (the cash and stock) plus setting up a comprehensive, multi-year royalty payment system. The payment doesn't just end; it continues for over a decade, flowing to the sellers every time a newly perfected watch model (a successful drug) leaves the workshop, ensuring the sellers benefit as the workshop gets more valuable over time.

🧩 Final Takeaway 📌

Amneal is executing a massive, structured acquisition of Kashiv BioSciences, leveraging an initial $375 million cash and stock payment. The bulk of the deal value ($350M+ potential) is contingent on successfully obtaining crucial FDA approvals and subsequent commercial launches, backed by long-term, high-growth royalty payments.